Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

In this study, rosemary essential oil and banyan aerial roots were used to develop a hair serum aimed at addressing hair fall and dandruff, with evaluations showing successful determination of parameters like viscosity and pH.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This review summarizes the antioxidant and anticarcinogenic properties of Indian Gooseberry, its phytochemical composition, and its use in traditional Ayurvedic medicine, but reports no new clinical results.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This narrative review examined the potential of hibiscus leaves and apple skin as natural ingredients for hair tonics and reported their effectiveness in addressing hair loss, highlighting properties like strong antioxidant content and ability to strengthen hair roots.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

This report details the development of a PSR™ Terminalia extract with antioxidant and anti-aging potential, highlighting its rich composition in phenolic acids, polysaccharides, and organic acids, without new clinical results.

This study found that a combination of liquorice and aloe vera extracts, particularly combination 1, resulted in the most optimal hair growth in rabbits over a 28-day period.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

This study observed that a hair tonic containing 3% ethanolic extract of bidara leaves stimulated rabbit hair growth more effectively over 28 days than both distilled water and 2% minoxidil, attributing this effect to the extract's anti-inflammatory and antioxidant properties.

This study examined the effects of purified Albizia saponaria bark extract on hair growth in rabbits, finding that a 20% concentration of the extract increased hair weight significantly, though it was less effective than minoxidil.

In this study, the petroleum ether extract of Maharanga bicolor and Hibiscus rosa sinensis in Aloe vera gel showed improved hair growth initiation and completion times in rats, suggesting potential hair growth-promoting activity.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

This study found that applying aqueous bay leaf extract to skin graft wounds in rabbits reduced inflammation and improved tissue regeneration, leading to enhanced healing compared to untreated controls, particularly in terms of collagen organization, fibrosis, and inflammation modulation over a 21-day period.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This study found that Sanguisorba Officinalis Root Extract showed potential in reducing hair loss by inhibiting FGF-5 activity, extending hair growth phases in mice and reducing hair loss in human trials.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.